7/20/2011

A panel of FDA advisers voted 9-6 against endorsing the approval of dapagliflozin, Bristol-Myers Squibb and AstraZeneca's drug candidate for type 2 diabetes. Advisers said clinical data do not provide substantial evidence of dapagliflozin's efficacy and risks.

Full Story:
Reuters

Related Summaries